Inmune Bio ( (INMB) ) has released its Q4 earnings. Here is a breakdown of the information Inmune Bio presented to its investors.
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to combat diseases, particularly in the fields of inflammation and immunology. The company is known for its innovative platforms like DN-TNF, CORDStrom™, and INKmune®.
INmune Bio Inc. recently announced its financial results for the year ending December 31, 2024, along with updates on its various clinical trials and corporate activities. The company has been actively advancing its clinical programs, particularly in Alzheimer’s Disease, Recessive Dystrophic Epidermolysis Bullosa, and metastatic castration-resistant prostate cancer.
Key highlights from the report include the completion of patient enrollment in the Phase 2 trial for Alzheimer’s Disease, significant progress in the CORDStrom™ platform for treating epidermolysis bullosa, and promising safety and efficacy data from the INKmune® platform in cancer treatment. Financially, the company reported a net loss of $42.1 million for 2024, with increased research and development expenses reflecting its active clinical pipeline.
Despite the financial loss, INmune Bio successfully raised approximately $27.5 million through securities purchase agreements and additional funds through its ATM program, strengthening its financial position to support ongoing and future clinical trials.
Looking ahead, INmune Bio is poised to release top-line results from its Alzheimer’s trial in mid-2025 and continue advancing its clinical programs, with the potential for regulatory filings and further development milestones in the coming years.